



Innovating for  
affordable healthcare

# Shilpa Medicare Limited

**Manufacturers and Exporters of Bulk Drugs**

"Shilpa House" # 12-6-214/A1, Hyderabad Road,  
RAICHUR - 584 135. Karnataka, India.

Phone : +91-8532 - 238704, Fax : +91-8532-238876

E-mail : info@vbshilpa.com Website : www.vbshilpa.com

GST NO : 29AADCS8788F1Z0

CIN No. L85110KA1987PLC008739

Dated: 05 Oct, 2019

Corporate Relationship Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
**Mumbai-400 001**

National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
**MUMBAI-400 051**

Dear Sir/Madam,

**Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.  
Ref: Stock Code: NSE: SHILPAMED/BSE-530549**

\*\*\*\*\*

This is to inform you that the Company has received U.S Food and Drug Administration final approval for its ANDA, Gemcitabine Injection, 200 mg/5.26 mL, 1 g/26.3 mL, and 2 g/52.6 mL (38 mg/mL) Single-dose vials on 04 Oct 2019.

Gemcitabine Injection, 200 mg/5.26 mL, 1 g/26.3 mL, and 2 g/52.6 mL (38 mg/mL) is used in the treatment of Ovarian Cancer, Breast Cancer, Non-Small Cell Lung Cancer and Pancreatic Cancer as recommended in the label approved by FDA.

According to IQVIA MAT Q2 2019 data, the US market for Gemcitabine Injection, 38 mg/mL is approximately US\$ 14.9 Million.

This is for your information and doing the needful.

With Regards,

**For SHILPA MEDICARE LIMITED**

**Sushil Bajaj**  
Chief Financial Officer

